US · Healthcare · Biotechnology
EPS came in at -0.34 against a street estimate of -0.41 — a beat of 17.1%.
Analysts rate NewAmsterdam Pharma Company N.V. Ordinary Shares a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $51.45.
| Fund | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 14.49% |
| Capital World Investors | 9.50% |
| RA Capital Management, LLC | 8.17% |
| FCPM III SERVICES BV | 7.87% |
| FMR Inc | 7.50% |
| Bain Capital Life Sciences Investors, LLC | 6.25% |
| Wellington Management Company LLP | 4.38% |
| Deerfield Management Co | 3.65% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 | 2026-07-24 |
| Board / officer change · Q3 2026 | 2026-07-22 |
| Board / officer change · Q2 2026 | 2026-06-03 |
| Results announced · Q2 2026 | 2026-05-07 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-05-06 |
| Annual report FY2025 | 2026-02-18 |
| Quarterly report · Q3 2025 | 2025-11-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for NewAmsterdam Pharma Company N.V. Ordinary Shares — free to start.
Google PlayApp StoreData updated 2026-08-05.